Circulating Tumor Cells Market Share, Size, Trends, Industry Analysis Report, By Technology (CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis); By Application (Clinical/Liquid Biopsy, Research); By Product; By Specimen; By Region; Segment Forecast, 2021 - 2028

Report Summary

全球循环肿瘤细胞的市场价值ed at USD 9.81 billion in 2020 and is expected to grow at a CAGR of 13.4% during the forecast period. Numerous potential applications of the circulating tumor cells in pre-diagnosis, efficient detection systems, advancement in the tumor biomarkers coupled with related technological advancements offer lucrative growth opportunities for the market.

Cancer tumor cells as a real-timeliquid biopsymethod represent a promising approach for the personalized treatment in oncology. Circulating tumor cells are used for early diagnosis, molecular phenotyping, looking for cancer relapse cases, prognosis prediction, and post-therapy evaluation. Moreover, metastasis starts with the shredding of circulating tumor cells from primary tumor cells into the circulatory system.

Know more about this report:request for sample pages

Circulating Tumor Cells Market Report Scope

The market is primarily segmented on the basis of technology, application, product, specimen, and region.

By Technology	By Application	By Product	By Specimen	By Region
Circulating Tumor Cells Detection & Enrichment Methods Immunocapture Size-based Separation Density-based Separation Combined Methods Circulating Tumor Cells Direct Detection Methods SERS Microscopy Others Circulating Tumor Cells Analysis	Clinical/ Liquid Biopsy Research	Kits & Reagents Blood Collection Tubes Devices or Systems	Blood Bone Marrow Other Body Fluids	North America (U.S., Canada) Europe (France, Germany, UK, Italy, Spain, Netherlands, Austria) Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea) Latin America (Brazil, Mexico, Argentina) Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

Know more about this report:request for sample pages

Insight by Technology

Advancements in chip technology are a key prominent driver for the market growth in circulating tumor cells. As per a market study published, in 2019, researchers at the Worcester Polytechnic Institute, chip from carbon nanotubes to overcome the challenges in capturing and isolating of circulating tumor cells. Moreover, the rising preference for companion diagnostics has also favored the market demand for circulating tumor cells in tumor cell detection procedures.

Furthermore, advancements in cell analysis technologies such as FISH, qPCR, and NGS have also increased the clinical utility of circulating tumor cells, thus accelerating the segment’s growth prospects. Most of the companies in the market are investing heavily in circulating tumor cells analysis and downstream assays. For instance, U.S.-based market company, Vortex Biosciences offers innovative circulating tumor cells analysis products and services, including cytogenetics using FISH, cytopathology, immuno-fluorescence, and cell culture.

Insight by Product

In 2020, the devices market segment of circulating tumor cells accounted for the largest revenue share. This high share is due to advances in microfluidic technology, and the development of automated instruments, which eliminates the use of adjunct blood collection tubes. Companies involved in the sector include companies involved in polyp assortment, independent labs, and the companies providing downstream services for circulating tumor cells analysis and accessories providers.

However, the kits and reagents market segment is projected to witness a lucrative growth rate over the study period. This is due to its extensive and repeated use during diagnosis. Moreover, multiple cancer lines have also been tested by a group of researchers using these kits to offer label-free cells and subsequently could be used in downstream services and analysis.

Insight by Specimen

In 2020, the blood specimen segment of the circulating tumor cells market accounted for the largest revenue share. Such a major share is due to the high concentration of circulating tumor cells in blood samples. Approaches towards tumor cell identification in blood samples are regarded as the most important step in cancer cell research, as it helps in prognosis and helps in assessing chemotherapy sessions.

在过去的几年里,大量的研究ctivities have been done on disseminated tumor cells, a circulating cancerous cell residing in the adjacent target tissues. Moreover, advancements in techniques have effectively accelerated genome variations among these cells, thereby driving the segment’s market growth prospects.

Geographic Overview

Geographically, the global market is bifurcated into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America is the largest market revenue contributor followed by Europe and the Asia Pacific region. In 2020, the North America region accounted for over 42 percent of the global market.

Continued market growth in the circulating tumor cells market in the region is attributed to the presence of active players such as CellTraffix, Inc., Biocept, Inc., and Aviva Biosciences. These players are actively holding their strategic dominance through innovative initiatives. In this direction, in 2019, Biocept, introduced Target Selector pan-TRK assay to detect TRK proteins. The assay is able to detect alterations in the TRK gene. These initiatives resulted in presence of non-invasive and cost-effective biomarkers for cancer detection.

Furthermore, the high prevalence of cancer and well-developed clinical infrastructure also favored the region’s growth. Asia Pacific is projected to witness a lucrative growth rate over the study period, owing to huge unmet patient medical needs, advancements in cancer biology, and increased cancer screening, coupled with government support.

Competitive Insight

The prominent players operating in the marketplace are Greiner Bio-One; BioFluidica, QIAGEN; Bio-Techne Corporation; Rarecells Diagnostics, ScreenCell, Menarini Silicon Biosystems; Fluxion Biosciences, Sysmex Corporation; Miltenyi Biotec, and Biocept, Inc.